{"id":"W4229068667","doi":"10.1016/j.annonc.2022.03.183","title":"164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Gemcitabine; Pembrolizumab; Internal medicine; Breast cancer; Oncology; Cancer; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00110234,0.0006041466,0.00136554,0.0002323177,0.0003328907,0.0006926285,0.0004575982,0.000749724,0.007007229],"category_scores_gemma":[0.0007019068,0.0002972024,0.002424781,0.0003574908,0.0004210155,0.0006193379,0.00052763,0.001854665,0.0007820626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006685074,"about_ca_system_score_gemma":0.0008384386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001869055,"about_ca_topic_score_gemma":0.003401171,"domain_scores_codex":[0.9996099,0.0001616147,0.00002975086,0.00007158524,0.00004387568,0.000083345],"domain_scores_gemma":[0.9995472,0.0001094983,0.0001102257,0.00003607182,0.00003651464,0.0001604831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9120772,0.01779009,0.006214738,0.0009241543,0.002740961,0.00003036746,0.00008194712,0.0004602527,0.007357643,0.0001212154,0.002254193,0.04994721],"study_design_scores_gemma":[0.5310349,0.3716886,0.08296078,0.0001925501,0.005391902,0.0001001161,0.0001512894,0.0005011483,0.003460164,0.0002574995,0.004215331,0.00004574647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868488,0.005575653,0.0001575359,0.0006182165,0.0002067613,0.0006454477,0.003417805,0.00002965098,0.002499988],"genre_scores_gemma":[0.9862082,0.00385582,0.0007012018,0.0008469259,0.0002604055,0.0009346847,0.003644284,0.000012585,0.003535939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007007229,"threshold_uncertainty_score":0.02344155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07916337031695886,"score_gpt":0.403148765976774,"score_spread":0.3239853956598151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}